Tumor mutation burden and PD-L1 expression in SDH/FH mutated solid tumors Evidence for selective silencing of MHC-binding neoepitopes to avoid immune surveillance CMS subtypes characterized by high TMB shows immunosuppressive microenvironment that implies resistance to immunotherapy Genomic and immune infiltration differences between MSI and MSS GI tumors Comprehensive-omic analysis of 152 CRC patients allows greater subclassification than CMS or sidedness alone Clinical trial screening of CDKN2A genomic alterations in patients with Pancreatic cancer and Hepatobiliary cancers requires greater precision than somatic sequencing alone Comprehensive characterization of immune landscape in gastrointestinal cancers and head and neck cancers via computational deconvolution Proteomic Analysis of Therapeutic Biomarkers to Guide Treatment of Patients with Bone Metastases Selecting Patients with Stage II or III Colorectal Cancer for 5Fluorouracilbased Adjuvant Chemotherapy Using Proteomic Analysis The Prognostic Role of Microsatellite Status, Tumor Mutational Burden, and Protein Expression in Colorectal Cancer Identifying Patients Sensitive to AnthracyclineContaining Therapy with Quantitative Proteomic and Genomic Profiling SLFN11 Expression in Early Stage NonSmall Cell Lung Cancer Correlates with Benefit from PlatinumContaining Chemotherapy Identifying Responders to Temozolomide Among Patients with Metastatic Colorectal Cancer Using Proteomic Quantitation of MGMT Predicting Overall Survival in Gastric Cancer Patients Randomized to Chemotherapy: A Reevaluation of the ITACAS Trial Proteomic Quantitation of ERCC1 May Predict Response to PlatinumBased Chemotherapy in Patients with NonSmall Cell Lung Cancer Quantitative Proteomic Analysis of MGMT May Predict Response of Colorectal Cancer Patients to Treatment with Temozolomide Quantification of FGFR Protein Expression in Solid Tumors by Targeted Mass Spectrometry and Correlation with FGFR Gene Amplification Status Using “Omics” to Select Immunotherapy and Conventional Therapy Combinations Proteomic Analysis of MET Tyrosine Kinase Receptor as a Prognostic Biomarker of Survival in Patients with Gastroesophageal Cancer Entering the Era of Clinical Proteomics: Utilizing Multiplexed Targeted Proteomics to Identify GC Patients Who May Benefit from Docetaxel: Reevaluation of the ITACAS trial Proteomic Analysis of ERCC1 Predicts Benefit of Platinum Therapy in NSCLC: A Reevaluation of Samples from the TASTE Trial Clinical mass spectrometrybased proteomics unlocks personalized medicine potential from bone metastases Mass spectrometrybased proteomic analysis may improve identification of patients sensitive to FGFR inhibitor therapy Identifying patientspecific neoepitopes for cellbased and vaccine immunotherapy across breast cancer classifications reveals rarely shared recurrent neoepitopes Identifying Patientspecific Neoepitopes for Cellbased and Vaccine Immunotherapy within the Cancer Genome Atlas Reveals Rarely Shared Recurrent Neoepitopes Identifying Patientspecific Neoepitopes for Cellbased and Vaccine Immunotherapy within the Cancer Genome Atlas Reveals Rarely Shared Recurrent Neoepitopes Exploratory study of NQO1 expression in advanced solid tumors. Identifying Patientspecific Neoepitopes for Cellbased and Vaccine Immunotherapy Targets in Breast Cancer Patients by HLA Typing and Predicting MHC Presentation from Whole Genome and RNA Sequencing Data. Highthroughput Identification of Neoepitopes for Development of Patientspecific Cancer Immunotherapies Quantitative HER2 protein expression analysis in multiple cancer indications: Identification of candidates for HER2 targeted therapies KRAS gene amplification defines a distinct molecular subgroup of gastroesophageal adenocarcinoma Quantitative HER family proteins assessment as prognostic and predictive biomarkers in the EGF30008 clinical trial Integrating Whole Exome Sequencing Data with RNASeq And Quantitative Proteomics to Better Inform Clinical Treatment Decisions in Patients with Metastatic Triple Negative Breast Cancer Integrating Whole Genome Sequencing Data With RNAseq, Pathway Analysis, and Quantitative Proteomics to Determine Prognosis After Standard Adjuvant Treatment With Trastuzumab and Chemotherapy in Primary Breast Cancer Patients Whole genome sequencing and quantitative proteomics reveal HPV integration and HER2 overexpression in a patient with cervical cancer: Comprehensive omics analysis driving clinical treatment decisions Building patientspecific predictors of drug responses from cell line genomics Genomics, Transcriptomics, and Proteomics in the Clinical Setting: Integrating Whole Genome and RNA Sequencing With Quantitative Proteomics to Better Inform Clinical Treatment Selection HER2 Quantification By Targeted Proteomics Compared To IHC Or ISH In Predicting Clinical Benefit From AntiHER2 Therapy In HER2positive Breast Cancer Proteomic analysis of primary and metastatic breast cancers reveals a wide range of expression of the folate receptor, a potential drug target Quantitative measurement of HER2 levels by targeted proteomics predicts survival in gastric cancer patients treated with trastuzumab Diagnostic protein quantitation of actionable targets in patient biopsies using clinical mass spectrometry Her2 expression in gastroesophageal cancer (GEC) FFPE tissue using mass spectrometry (MS) and correlation with HER2 gene amplification Quantitative measurement of HER2 levels by multiplexed mass spectrometry from FFPE tissue predicts survival in patients treated with antiHER2 based therapy Development and Clinical Validation of a Quantitative Mass Spectrometric Assay for PDL1 Protein in FFPE NSCLC Samples Quantification of ALK from NonSmall Cell Lung Cancer (NSCLC) FFPE Tissue by Targeted Mass Spectrometry High Levels of HER2 Measured By Multiplex Mass Spectrometry Correlate With Increased Overall Survival In Patients Treated With AntiHER2 Therapy A comprehensive analysis of molecular profiles across over 10,000 tumor and germline exomes from over 5,000 patients across more than 20 tumor types Differential pathway activation associated with domainspecific PIK3CA mutations Development and Clinical Validation of a Quantitative Mass Spectrometric Assay for PDL1 Protein in FFPE NSCLC Samples Towards personalized treatment for gastroesophageal adenocarcinoma: Strategies to address inter and intra patient tumor heterogeneity: PANGEA Quantification of MET Expression Using Mass Spectrometry (MS): Assay Precision and Stability in FFPE Tumor Tissue Multiplexed Mass Spectrometrybased Assay to Quantify Translocation Markers from NSCLC FFPE Tissue Learning Regulatory Interactions with Paradigm Learning regulatory links in cancer through integrated pathway analysis with Paradigm Development of a Quantitative Gastroesophageal Cancer SRM assay for Use in FFPE Tumor Tissues FOXM1 target genes associated with cell cycle regulation predict breast cancer metastatic outcome Quantification of HER2 from Gastroesophageal Cancer (GEC) FFPE Tissue by Mass Spectrometry (MS) Mass Spectrometry Based Quantitative Analysis of the HER Family receptors in FFPE Breast Cancer Tissue Singlecell RNA sequencing of paclitaxeltreated breast cancer cell lines to find individual cell response Development of a Quantitative Gastroesophageal Cancer Selected Reaction Monitoring Mass Spectrometric Multiplex Assay for Use in FFPE Tissues Cancer genome sequencing analysis, storage, discovery and delivery Integrated Genomic and Pathway Analysis Reveals Key Pathways across Breast Subtypes
